Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s271, 2023. DOI: 10.25251/skin.7.supp.271. Disponível em: https://skin.dermsquared.com/skin/article/view/2382. Acesso em: 19 apr. 2026.